<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894228</url>
  </required_header>
  <id_info>
    <org_study_id>GIS-DUMBO-2018</org_study_id>
    <nct_id>NCT03894228</nct_id>
  </id_info>
  <brief_title>Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)</brief_title>
  <official_title>Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Agency of Medicines and Health Products</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, multicenter registry, which will enrol pregnant women
      with IBD (CD, UC, or unclassified IBD) over 5 years in Spain.

      In addition, each incident gestation will be followed-up during pregnancy, and children born
      to those mothers will be followed-up over 4 years to determine the incidence of serious
      adverse events (such as alteration of developmental status, infections, neoplasia or any
      other serious adverse events) during the study period. In order to harmonize the inclusion of
      adverse events and complications, only serious adverse events will be registered . The main
      variable will be the development of serious infection in children as this is the outcome that
      had controversial results in previous studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES Main objective - To assess the safety of drugs used for IBD treatment both for
      pregnancy and for the offspring mainly focused on the risk of serious infections (from birth
      and in the first 4 years of life).

      Specific objectives

        -  To know the risk of serious adverse events (including abortions) during pregnancy and
           delivery associated with drugs used for the treatment of IBD.

        -  To asses the developmental status of children born from IBD mothers during the first 4
           years.

        -  To compare the relative risk of serious adverse events in children born from mothers
           with IBD who have been exposed in utero to different drugs to treat IBD with the risk in
           children who were not exposed.

        -  To compare the prevalence of malformations in children exposed to drugs to treat IBD in
           utero with the prevalence in children who were not exposed.

        -  To evaluate the relative risk of developing neoplasm in children exposed to drugs to
           treat IBD.

      Inclusion criteria

        -  Patients over 18 years of age diagnosed with IBD.

        -  Confirmed pregnancy.

        -  Awareness of the pregnancy (by the researcher) before week 28th of gestation (the end of
           the second trimester).

      Exclusion criteria. - Patients who do not accept to participate in the study Study cohorts

      - Biologics exposed cohort: Children born from mothers treated with biologic drugs (with or
      without immunomodulators) at any time during pregnancy or the three months before conception.
      Biologic drugs are IgG monoclonal antibodies able to cross the placenta.

        -  Immunomodulators exposed cohort: Children born from mothers treated with
           immunomodulators (without biologics) during pregnancy or the three months before
           conception.

        -  Non-exposed cohort: Children born from mothers treated neither with biologic drugs nor
           with immunomodulators at any time during pregnancy or the three months before
           conception.

      Tasks and responsibilities:

      IBD specialists from the participating centers will be responsible for identifying the
      patients, obtaining the informed consent and registering them in the database.

      Each participating investigator will register all the demographic and clinical data of the
      mother at the time of entering in the study and will contact the pregnant woman at the end of
      first trimester, the end of second trimester, the end of third trimester and one month after
      delivery to prospectively include information about disease activity, treatments and serious
      adverse events (if any) during pregnancy and delivery. If the mother contacts the clinician
      (researcher) after the end of the first trimester but before the end of the second trimester
      of gestation, the case can be included and data up to the entry date registered
      retrospectively. In order to ensure data quality, patients who inform about the pregnancy
      after the end of the second trimester of gestation will be excluded.

      After birth, the mother will be contacted every 3 months to include information about the
      child development and serious adverse events (mainly malformations, infections, hospital
      admissions or neoplasias such as developmental tumors). After consenting, contact information
      of the mother will be shared with the research team in Hospital Universitario de La Princesa
      in order to complete the information every 3 months. On a yearly basis, the mothers will
      provide the site investigator with the reports that support the information given in the
      remote contact. In addition, in the first visit after birth, mothers will be provided with
      the Ages and Stages Questionnaire (ASQ 3, annex 2) that should be completed during follow-up
      (2, 4, 6, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 27, 30, 33, 36, 42, 48 months of age). The
      mother should give the questionnaire she has completed once per year. External monitoring of
      cases included in the registry will also be performed by review of some cases selected at
      random by the research team of Hospital Universitario de La Princesa.

      Definitions

        1. Disease location and phenotype: IBD location and phenotype will be defined according to
           the Montreal classification.

        2. Date of conception: It will be defined as the date of last menstruation before becoming
           pregnant.

        3. Smoking: Smoking status will be categorized as &quot;non-smoker&quot;, &quot;smoker&quot;, or &quot;ex-smoker&quot;,
           and will be considered at the time of conception. Patients will be considered &quot;smokers&quot;
           if they smoked more than 7 cigarettes per week for at least 6 months prior to
           conception. Patients will be considered &quot;ex-smokers&quot; if they quit smoking before
           conception. Patients will be considered &quot;non-smokers&quot; if they never smoked.

      3. Diagnosis of pregnancy: Elevated human chorionic gonadotropin (hCG) hormone in blood or
      urine (biochemical pregnancy).

      4. Miscarriage: Natural death of an embryo or fetus before it is able to survive
      independently.

      5. Elective abortion: The removal of an embryo or fetus from the uterus in order to end a
      pregnancy.

      6. Comorbidities: Mother's diseases, with special mention to hypertension, diabetes mellitus,
      seizure disorders, thyroid disorders, allergic disorders, heart diseases, connective tissue
      diseases, autoimmune diseases, hepatitis.

      7. Known risk factors for adverse pregnancy outcomes, including environmental or occupational
      exposure, among others.

      8. Treatments: Treatments received by the mother in the 3 months before conception, during
      pregnancy and breastfeeding will be recorded.

      9. Serious adverse events: In order to harmonize the inclusion of adverse events and
      complications, only serious adverse events will be registered (see the definition of adverse
      events in the Annex 1 of the protocol). Nevertheless, the investigators have predefined the
      most frequent serious adverse events during pregnancy and in the offspring. In this respect,
      the main variable in our study will be the development of serious infection in the offspring
      (infection meeting criteria of serious adverse event).

      9.1. Serious adverse events during pregnancy: Any event that meets the criteria of serious
      adverse event will be registered in the database. Some of the most frequent serious adverse
      events during pregnancy are specifically defined and inquired by the registry: abortion,
      stillbirth, growth retardation, serious infection, eclampsia, placenta previa,
      chorioamnionitis, or abruptio placenta. Abnormalities found in the 20th week ultrasound will
      be registered (although malformations should be confirmed after birth and included in the
      Serious Adverse Events section of the newborn). Fetal malformations that lead to abortion or
      stillbirth will be included as cause of abortion or cause of stillbirth in their specific
      sections (Serious adverse events of the mother).

      9.2. Serious adverse events during delivery: Serious adverse events, such as instrumental
      delivery or preterm delivery will be registered in the Serious adverse events of the mother
      section. The admission for delivery will not be considered as a serious adverse event, but
      any event causing prolongation of the admission will be considered as a serious adverse event
      and registered in the specific section.

      9.3. Serious adverse events in the newborns and children: Serious adverse events in the
      newborn and children, such as congenital malformations, admission to the intensive care unit,
      low birth weight, hypoxic-ischemic encephalopathy, neonatal stroke or low Apgar score, severe
      infections and tumors will be included.

      10. Preterm delivery: Delivery before week 37 of gestation18, 19. 11. Low birth weight:
      &lt;2,500 mg18, 19. 12. IBD activity: The IBD activity will be assessed at conception (when the
      physician is aware of the pregnancy) and in each trimester of gestation based on the
      Harvey-Bradshaw for CD and Partial Mayo Score for UC patients.

      13. Low Apgar score: Apgar scores lower than 7 are considered low, and scores of 7 or higher
      are considered normal at ten minutes after birth20.

      14. Serious infection: Only infections that meet the criteria of serious adverse event will
      be included. The inclusion of any infection, irrespective of its seriousness, would be very
      heterogeneous among investigators, leading to reporting bias which might affect the
      interpretation of the results. This variable will be the main outcome.

      15. Developmental status: The developmental status will be assessed by the ASQ-3
      questionnaire (annex 2). The mothers will complete the questionnaire at home and send the
      completed forms yearly to their treating clinicians.

      Data collection and follow-up After the case is registered, four other visits will be
      recorded during pregnancy, coinciding with the routine visits of the patient for the
      follow-up of her disease. After delivery, the children will be followed-up until the age of 4
      years. In case of multiple gestations, each child will be considered as a case with his/her
      own follow-up. Only live newborns will be considered cases. Abortions or stillbirths will be
      registered as mothers' adverse events. In multiple gestations, the number of fetuses affected
      by a certain serious adverse event will be indicated in the CRF. During the child's follow-up
      period, the mother (that is the patient, indeed) will be contacted remotely every-three
      months to complete information about child complications (if any). The visits over the study
      are described below. The variables included in the eCRF are listed in Annex 3.

        -  Visit 0 (baseline): inclusion of patient in the study (after confirmed pregnancy) and
           registration of clinical data (characteristics of the disease, disease activity and
           treatments).

        -  Visit 1 (end of first trimester of gestation): Updating of data related to treatment,
           disease activity and serious adverse events (if any).

        -  Visit 2 (end of second trimester of gestation): Updating of data related to treatment,
           disease activity and serious adverse events (if any).

        -  Visit 3 (end of third trimester of gestation): Updating of data related to treatment,
           disease activity and serious adverse events (if any).

        -  Visit 4 (1 month after delivery): Updating of data related to treatment, disease
           activity and serious adverse events (if any). In addition, in this visit, the child will
           be registered in the database as a case. Information of the newborn, such as date of
           birth, sex, birth weight, Apgar score (at 5 and 10 minutes), vaccines, breastfeeding,
           serious adverse events, etc., will be included.

        -  Visit 5 (3 months of age, 2 months after visit 4) to 20 (4 years of age): Updating of
           data related to children development, vaccines, breastfeeding, date of schooling,
           infections, hospitalizations, allergies or any other complications. The same data will
           be queried to the mother every-three months after the age of 4 years. Remote contacts
           will be allowed to complete the children information, as the investigators believe that
           this way of obtaining information will not have impact on the quality of data and will
           improve the adherence to the protocol. Nevertheless, once per year data should be
           confirmed with medical reports provided by the mothers.

      Study data will be collected and managed using an electronic data capture tool (Research
      Electronic Data Capture [REDCap]1, 18, 19), which is hosted at Asociación Española de
      Gastroenterología21, a non-profit scientific and medical society focusing on
      gastroenterology. AEG provides this service free of charge, with the sole aim of promoting
      independent investigator-driven research. REDCap is a secure, web-based application designed
      to support data capture for research studies that provides the following: 1) an intuitive
      interface for validated data entry; 2) audit trails for tracking data manipulation and export
      procedures; 3) automated export procedures for seamless data downloads to common statistical
      packages; and 4) procedures for importing data from external sources.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>57 Months</target_duration>
  <primary_outcome>
    <measure>To calculate the incide rate of serious infections during pregnancy (evaluated and the end of pregnancy) based on the medications used to treat IBD.</measure>
    <time_frame>9 months</time_frame>
    <description>To assess the prevalence of complications related to drugs used for IBD treatment for pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To calculate the incide rate of serious infections for the offspring (at eh age of 4 years) based on the medications used to treat IBD.</measure>
    <time_frame>4 years</time_frame>
    <description>To assess the prevalence of complications related to drugs used for IBD treatment for the offspring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To calculate the incide rate of serious adverse events during pregnancy (evaluated at the end of pregnancy) based on the medications used to treat IBD.</measure>
    <time_frame>9 months</time_frame>
    <description>To asses the prevalence of complications related to drugs used for IBD treatment for pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To calculate the incide rate of serious adverse events during offspring (at the age of 4 years) based on the medications used to treat IBD.</measure>
    <time_frame>4 years</time_frame>
    <description>To asses the prevalence of complications related to drugs used for IBD treatment for offspring mainly focused on the risck of serious infections at the age of 4 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. To calculate the Odds ratio of serious adverse events (including abortions) during pregnancy and delivery based on the drugs used for the treatment of IBD.</measure>
    <time_frame>4 years and 9 months</time_frame>
    <description>To know the risk of serious adverse events (including abortions) during pregnancy and delivery associated with drugs used for the treatment of IBD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. To measure the developmental status of children born from IBD mothers with the ASQ-3 questionnaire during the first 4 years.</measure>
    <time_frame>4 years and 9 months</time_frame>
    <description>To asses the developmental status of children born from IBD mothers during the first 4 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. To calculate the Hazard ratio of serious adverse events in children born from mothers with IBD who have been exposed in utero to different drugs to treat IBD with the risk in children who were not exposed.</measure>
    <time_frame>4 years and 9 months</time_frame>
    <description>To compare the relative risk of serious adverse events in children born from mothers with IBD who have been exposed in utero to different drugs to treat IBD with the risk in children who were not exposed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. To calculate the proportion of children with malformations and to compare the proportions between exposure groups (children exposed to biologics with those non exposed to these drugs).</measure>
    <time_frame>4 years and 9 months</time_frame>
    <description>To compare the prevalence of malformations in children exposed to biologics to treat IBD in utero with the prevalence in children who were not exposed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. To calculate the Hazard ratio of developing neoplasm in children exposed to drugs to treat IBD.</measure>
    <time_frame>4 years and 9 months</time_frame>
    <description>To evaluate the relative risk of developing neoplasm in children exposed to drugs to treat IBD.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1750</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Biologics exposed cohort</arm_group_label>
    <description>Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunomodulators exposed cohort</arm_group_label>
    <description>Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposed cohort</arm_group_label>
    <description>Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with IBD (CD, UC, or unclassified IBD) over 5 years in Spain.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age diagnosed with IBD.

          -  Confirmed pregnancy.

          -  Awareness of the pregnancy (by the researcher) before week 28th of gestation (the end
             of the second trimester).

        Exclusion Criteria:

        • Patients who do not accept to participate in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María Chaparro, PhDMD</last_name>
    <phone>913093911</phone>
    <email>mariachs2005@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María G Donday</last_name>
    <phone>913093911</phone>
    <email>mariagdonday@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Barreiro</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Barreiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Manuel Benítez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>María del Pilar Martínez Tirado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aurora Talavera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Juan Ramón Jimenez</name>
      <address>
        <city>Huelva</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan María Vázquez Morón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Victor Manuel Navas López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guillermo Alcaín Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios del Aljarafe</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yolanda Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Leo Carnerero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Jorge</name>
      <address>
        <city>Huesca</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Miguel Montoro Huguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopsital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raquel Vicente Lidón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maite Arroyo Villarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Royo Villanova</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mara Charro Calvillo, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabino Riestra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Ginard Vicens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Negrin</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Ceballos</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Ceballos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de la Candelaria</name>
      <address>
        <city>Tenerife</city>
        <state>Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlos Tardillo Marín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Montse Rivero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellon</name>
      <address>
        <city>Castellon de la Plana</city>
        <state>Castellón</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pedro Almela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alcázar de San Juan</name>
      <address>
        <city>Ciudad Real</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esther Berrardos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tomelloso</name>
      <address>
        <city>Ciudad Real</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfredo J Lucendo, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Hervías Cruz, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <state>Castilla La Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Concha Muñoz, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santos Reyes</name>
      <address>
        <city>Burgos</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luis Hernández Villalba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lara Arias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fernando Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Noelia Alcaide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Zamora</name>
      <address>
        <city>Zamora</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paola María Fradejas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Concha</name>
      <address>
        <city>Zamora</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana María Fuentes Coronel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lucía Márquez Mosquera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Ricart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandra Ruiz cerulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesc Casellas Jordá, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Busquets Casals, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Manresa</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Empar Sáinz Arnau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Tarragona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marta Piqueras Cano, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Menacho Viladot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Tarragona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francisco J Martínez Cerezo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marina Baixa de Villajoyosa</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio García Hérola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gloria García del Castillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Mª Huguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyís de Xátiva</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Joaquín Ramírez Palanca, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitàri i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mariam Aguas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro Alcántara</name>
      <address>
        <city>Cáceres</city>
        <state>Extremadura</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carmen Dueñas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ferrol</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Echarri Piudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Teresa Diz-Lois Palomares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pablo Vega Villaamil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vicent Hernández Ramírez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Comaral de Inca</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Reyes Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pilar López Serrano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Isabel Vera Mendoza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitario Infanta Cristina</name>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Belén Botella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>San Fernando De Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mari Carmen Rodríguez Grau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrejón</name>
      <address>
        <city>Torrejón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Va Domselaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saioa Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <state>Pais Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iago Rodríguez Lago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Álava</name>
      <address>
        <city>Alava</city>
        <state>País Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Ramírez de la Piscina Urraca, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <state>País Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luís Bujanda Ferández de Piérola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Granollers</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Victor Jair Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Chaparro</last_name>
    </contact>
    <investigator>
      <last_name>María Chaparro, IP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cristina Alba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mª Dolores Martín Arranz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pilar Martínez Montiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ignacio Marín Jiménez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Angel Ponferrada Díaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noemí Manceñido Marcos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos Castaño Milla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Sánchez Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rosell</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ivan García Tercero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Minguez</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Minguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010 May;16(5):881-95. doi: 10.1002/ibd.21154. Review.</citation>
    <PMID>19885906</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013 Sep;108(9):1426-38. doi: 10.1038/ajg.2013.171. Epub 2013 Jun 11. Review.</citation>
    <PMID>23752881</PMID>
  </reference>
  <reference>
    <citation>Burisch J, Pedersen N, Cukovic-Cavka S, Turk N, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Krabbe S, Andersen V, Dahlerup Jens F, Kjeldsen J, Salupere R, Olsen J, Nielsen KR, Manninen P, Collin P, Katsanos KH, Tsianos EV, Ladefoged K, Lakatos L, Bailey Y, O'Morain C, Schwartz D, Odes S, Martinato M, Lombardini S, Jonaitis L, Kupcinskas L, Turcan S, Barros L, Magro F, Lazar D, Goldis A, Nikulina I, Belousova E, Fernandez A, Hernandez V, Almer S, Zhulina Y, Halfvarson J, Tsai HH, Sebastian S, Lakatos PL, Langholz E, Munkholm P; EpiCom Group. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014 Jan;20(1):36-46. doi: 10.1097/01.MIB.0000436277.13917.c4.</citation>
    <PMID>24252978</PMID>
  </reference>
  <reference>
    <citation>Mix E, Goertsches R, Zett UK. Immunoglobulins--basic considerations. J Neurol. 2006 Sep;253 Suppl 5:V9-17. Review. Erratum in: J Neurol. 2008 Feb;255(2):308.</citation>
    <PMID>16998762</PMID>
  </reference>
  <reference>
    <citation>Israel EJ, Simister N, Freiberg E, Caplan A, Walker WA. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology. 1993 May;79(1):77-81.</citation>
    <PMID>8509144</PMID>
  </reference>
  <reference>
    <citation>Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol. 2011 May;12(5):765-73. Review.</citation>
    <PMID>21342120</PMID>
  </reference>
  <reference>
    <citation>Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016 Jul;151(1):110-9. doi: 10.1053/j.gastro.2016.04.002. Epub 2016 Apr 8.</citation>
    <PMID>27063728</PMID>
  </reference>
  <reference>
    <citation>Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012 Sep;6(8):811-23. doi: 10.1016/j.crohns.2012.04.009. Epub 2012 May 16. Review.</citation>
    <PMID>22595185</PMID>
  </reference>
  <reference>
    <citation>Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Biron AI, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Shitrit BA, Gutierrez A, Doherty GA, Fernandez-Salazar L, Cadilla MJ, Huguet JM, OʼToole A, Stasi E, Marcos MN, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Palomares DM, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Bradley FI, Roman LA, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, de Carpi MFJ, Gisbert JP. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018 Mar;113(3):396-403. doi: 10.1038/ajg.2017.501. Epub 2018 Feb 20.</citation>
    <PMID>29460920</PMID>
  </reference>
  <reference>
    <citation>Domènech E, Gisbert JP. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. Gastroenterol Hepatol. 2016 Dec;39(10):677-686. doi: 10.1016/j.gastrohep.2015.11.010. Epub 2016 Mar 2. Review. English, Spanish.</citation>
    <PMID>26948838</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Domènech E. [Vedolizumab in the treatment of Crohn's disease]. Gastroenterol Hepatol. 2015 May;38(5):338-48. doi: 10.1016/j.gastrohep.2014.12.003. Epub 2015 Jan 23. Review. Spanish.</citation>
    <PMID>25619903</PMID>
  </reference>
  <reference>
    <citation>Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041. Epub 2017 Sep 1.</citation>
    <PMID>28870657</PMID>
  </reference>
  <reference>
    <citation>Lahat A, Shitrit AB, Naftali T, Milgrom Y, Elyakim R, Goldin E, Levhar N, Selinger L, Zuker T, Fudim E, Picard O, Yavzori M, Ben-Horin S. Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jan 5;12(1):120-123. doi: 10.1093/ecco-jcc/jjx120.</citation>
    <PMID>28961712</PMID>
  </reference>
  <reference>
    <citation>Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. Gastroenterology. 2018 Feb;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067. Epub 2017 Oct 5.</citation>
    <PMID>28988916</PMID>
  </reference>
  <reference>
    <citation>Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr;45(7):941-950. doi: 10.1111/apt.13960. Epub 2017 Feb 7.</citation>
    <PMID>28169436</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Chaparro M. Ustekinumab to treat Crohn's disease. Gastroenterol Hepatol. 2017 Dec;40(10):688-698. doi: 10.1016/j.gastrohep.2017.08.006. Epub 2017 Oct 16. Review. English, Spanish.</citation>
    <PMID>29042094</PMID>
  </reference>
  <reference>
    <citation>Rowan CR, Cullen G, Mulcahy HE, Keegan D, Byrne K, Murphy DJ, Sheridan J, Doherty GA. Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. J Crohns Colitis. 2018 Feb 28;12(3):376-378. doi: 10.1093/ecco-jcc/jjx141.</citation>
    <PMID>29045603</PMID>
  </reference>
  <reference>
    <citation>Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar;150(3):734-757.e1. doi: 10.1053/j.gastro.2015.12.003. Epub 2015 Dec 11. Review.</citation>
    <PMID>26688268</PMID>
  </reference>
  <reference>
    <citation>van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F; European Crohn’s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015 Feb;9(2):107-24. Review.</citation>
    <PMID>25602023</PMID>
  </reference>
  <reference>
    <citation>Boyd HA, Basit S, Harpsøe MC, Wohlfahrt J, Jess T. Inflammatory Bowel Disease and Risk of Adverse Pregnancy Outcomes. PLoS One. 2015 Jun 17;10(6):e0129567. doi: 10.1371/journal.pone.0129567. eCollection 2015.</citation>
    <PMID>26083614</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03894228/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

